About Cancer Biomarkers
Biomarkers are molecules present in the blood, other body fluids such as serum, urine, or in tissue that are indicators of a disease or abnormal conditions. Biomarkers are mostly used as diagnostic tools. Biomarkers help in identifying potential drug failures in initial stages, leading to savings in time and costs. Biomarkers are becoming an essential part of the drug discovery process. Cancer Biomarkers are proteins or metabolites indicative of tumor state and progression characteristics. They are non-invasive, enable high speed cancer diagnosis and also enhance early cancer detection and screening. The best example of a cancer biomarker is that of prostate specific antigen. PSA is measured in the blood to screen for and monitor treatment for prostate cancer. PSA, as a biomarker helps the doctors to monitor the progress of the cancer. It also helps to evaluate the response of the cancer to the treatment therapy.
TechNavio's analysts forecast the Global Cancer Biomarkers market to grow at a CAGR of 18.26 percent over the period 2014-2019.
Covered in this Report
TechNavio's report, Global Cancer Biomarkers Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Cancer Biomarkers market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
• APAC
• EMEA
Key Vendors
• Abbott Laboratories
• Affymetrix
• Illumina
• Qiagen
• Quest Diagnostics
• Roche Diagnostics
Other Prominent Vendors
• Agendia
• Agilent Technologies
• Alere
• Ambry Genetics
• Amgen
• Astellas Pharma US
• Astex Pharmaceuticals
• Atossa Genetics
• Beckman Coulter
• Becton, Dickinson and Company
• Biocurex
• bioMérieux
• Celldex Therapeutics
• Clarient
• diaDexus
• DiagnoCure
• Epigenomics
• EUSA Pharma
• Exact Sciences
• Foundation Medicine
• Fujirebio Diagnostics
• Genomic Health
• Geron
• Immunomedics
• Morphotek
• Myriad Genetics
• Nodality
• Northwest Biotherapeutics
• Ocimum Biosolutions
• Oncothyreon
• OriGene
• Polymedco
• Radient Pharmaceuticals
• Randox Laboratories
• Siemens Healthcare
• US Biomarkers
• Vermillion
Market Driver
• Increased Prevalence of Cancer
• For a full, detailed list, view our report
Market Challenge
• Regulatory and Reimbursement Issues
• For a full, detailed list, view our report
Market Trend
• Growing Popularity of Companion Diagnostics
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Incidence and Prevalence
08. Biomarkers Used in Cancer Diagnosis
08.1.1 Cancer Biomarkers : FDA Approved till 2012
08.1.2 Cancer Biomarkers : FDA Approved 2013
09. FDA Approval Process for Protein-Based Cancer Biomarkers
10. Geographical Segmentation
10.1 Cancer Biomarkers Market in the Americas
10.1.1 Market Size and Forecast
10.1.2 Cancer Biomarkers Market in US
10.2 Cancer Biomarkers Market in the EMEA Region
10.2.1 Market Size and Forecast
10.3 Cancer Biomarkers Market in APAC Region
10.3.1 Market Size and Forecast
11. Buying Criteria
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Trends and their Impact
18. Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.1.2 Mergers and Acquisitions
18.2 Vendor Analysis 2014
18.3 Other Prominent Vendors
19. Key Vendor Analysis
19.1 Abbott Laboratories
19.1.1 Key Facts
19.1.2 Business Description
19.1.3 Business Segmentation
19.1.4 Business Strategy
19.1.5 Revenue by Business Segmentation
19.1.6 Revenue Comparison 2011 and 2012
19.1.7 Revenue by Geographical Segmentation
19.1.8 Key Information
19.1.9 SWOT Analysis
19.2 Affymetrix
19.2.1 Key Facts
19.2.2 Business Overview
19.2.3 Business Segmentation
19.2.4 Business Segmentation by Revenue 2013
19.2.5 Business Segmentation by Revenue 2012 and 2013
19.2.6 Sales by Geography
19.2.7 Business Strategy
19.2.8 Key Information
19.2.9 SWOT Analysis
19.3 Illumina
19.3.1 Key Facts
19.3.2 Business Overview
19.3.3 Business Segmentation
19.3.4 Geographical Segmentation by Revenue 2013
19.3.5 Business Strategy
19.3.6 Key Information
19.3.7 SWOT Analysis
19.4 Qiagen
19.4.1 Key Facts
19.4.2 Business Overview
19.4.3 Product Segmentation by Revenue 2013
19.4.4 Product Segmentation by Revenue 2012 and 2013
19.4.5 Geographical Segmentation by Revenue 2013
19.4.6 Business Strategy
19.4.7 Recent Developments
19.4.8 SWOT Analysis
19.5 Quest Diagnostics
19.5.1 Key Facts
19.5.2 Business Overview
19.5.3 Business Segmentation by Revenue 2013
19.5.4 Business Segmentation by Revenue 2011-2013
19.5.5 Geographical Segmentation by Revenue 2013
19.5.6 Business Strategy
19.5.7 Recent Developments
19.5.8 SWOT Analysis
19.6 Roche Diagnostics
19.6.1 Key Facts
19.6.2 Business Overview
19.6.3 Business Segmentation by Revenue 2013
19.6.4 Geographical Segmentation by Revenue 2013
19.6.5 Business Strategy
19.6.6 Key Developments
19.6.7 SWOT Analysis
20. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Cancer Biomarkers Market 2014–2019 (US$ billion)
Exhibit 3: Incidence of Various Types of Cancer in 2012
Exhibit 4: FDA Classification of Medical Devices by Type of Class
Exhibit 5: Global Cancer Biomarkers Market by Geographical Segmentation 2014
Exhibit 6: Global Cancer Biomarkers Market by Geographical Segmentation 2019
Exhibit 7: Cancer Biomarkers Market in the Americas 2014-2019 (US$ billion)
Exhibit 8: Cancer Biomarkers Market in US 2014-2019 (US$ billion)
Exhibit 9: Cancer Biomarkers Market in the EMEA Region 2014-2019 (US$ billion)
Exhibit 10: Cancer Biomarkers Market in the APAC Region 2014-2019 (US$ billion)
Exhibit 11: Global Cancer Biomarkers Market by Geographical Segmentation 2014-2019
Exhibit 12: Abbott Laboratories Inc.: Business Segmentation
Exhibit 13: Abbott Laboratories Inc.: Revenue by Business Segmentation 2012
Exhibit 14: Abbott Laboratories Inc.: Revenue by Business Segmentation 2011 and 2012 (US$ million)
Exhibit 15: Abbott Laboratories Inc.: Revenue by Geographical Segmentation 2012
Exhibit 16: Affymetrix Inc.: Business Segmentation 2013
Exhibit 17: Affymetrix Inc.: Business Segmentation by Revenue 2013
Exhibit 18: Affymetrix Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 19: Affymetrix Inc.: Sales by Geography 2013
Exhibit 20: Illumina: Business Segmentation
Exhibit 21: Illumina: Geographical Segmentation by Revenue 2013
Exhibit 22: Qiagen: Product Segmentation by Revenue 2013
Exhibit 23: Qiagen: Product Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 24: Qiagen: Geographical Segmentation by Revenue 2013
Exhibit 25: Global Cancer Biomarkers Market: Business Segmentation by Revenue 2013
Exhibit 26: Global Cancer Biomarkers Market: Business Segmentation by Revenue 2011-2013 (US$ billion)
Exhibit 27: Global Cancer Biomarkers Market: Geographical Segmentation by Revenue 2013
Exhibit 28: Roche Diagnostics: Business Segmentation by Revenue 2013
Exhibit 29: Roche Diagnostics: Geographical Segmentation by Revenue 2013
